Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Surg Res. 2021 Jan 21;261:334–342. doi: 10.1016/j.jss.2020.12.045

Figure 5:

Figure 5:

HJC0416 inhibited pro-inflammatory cytokines and the NF-κB pathway

(B) ELISA for (A) IL-6 antibodies demonstrates that HJC0416 significantly inhibits LPS-induced expression. (B) IL-1ß and ICAM-1 expression is decreased after treatment with HJC0416. (C) HJC0416 decreases LPS-induced NF-κB nuclear translocation and DNA binding. (D) HJC0416 decreases LPS-induced NF-κB pathway activation. The results are representative of at least three different experiments.